164 related articles for article (PubMed ID: 38134265)
1. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling.
Hage S; Kinkade S; Girard R; Flemming KD; Kim H; Torbey MT; Huang J; Huston J; Shu Y; Selwyn RG; Hart BL; Mabray MC; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar-Felix RJ; Shenkar R; Hobson N; DeBiasse D; Lane K; McBee NA; Treine K; Ostapkovich N; Wang Y; Thompson RE; Koenig JI; Carroll T; Hanley DF; Awad IA
Stroke; 2024 Jan; 55(1):31-39. PubMed ID: 38134265
[TBL] [Abstract][Full Text] [Related]
2. Cavernous Angioma Symptomatic Hemorrhage (CASH) Trial Readiness II: Imaging Biomarkers and Trial Modeling.
Hage S; Kinkade S; Girard R; Flemming KD; Kim H; Torbey MT; Huang J; Huston J; Shu Y; Selwyn RG; Hart BL; Mabray MC; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar R; Shenkar R; Hobson N; DeBiasse D; Lane K; McBee N; Treine K; Ostapkovich N; Wang Y; Thompson RE; Mendoza-Puccini C; Koenig J; Carroll T; Hanley DF; Awad IA
medRxiv; 2023 Jun; ():. PubMed ID: 37333396
[TBL] [Abstract][Full Text] [Related]
3. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
Zeineddine HA; Girard R; Cao Y; Hobson N; Fam MD; Stadnik A; Tan H; Shen J; Chaudagar K; Shenkar R; Thompson RE; McBee N; Hanley D; Carroll T; Christoforidis GA; Awad IA
J Magn Reson Imaging; 2018 Apr; 47(4):1133-1138. PubMed ID: 28791783
[TBL] [Abstract][Full Text] [Related]
4. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.
Girard R; Fam MD; Zeineddine HA; Tan H; Mikati AG; Shi C; Jesselson M; Shenkar R; Wu M; Cao Y; Hobson N; Larsson HBW; Christoforidis GA; Awad IA
J Neurosurg; 2017 Jul; 127(1):102-110. PubMed ID: 27494817
[TBL] [Abstract][Full Text] [Related]
5. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome.
Flemming KD; Kim H; Hage S; Mandrekar J; Kinkade S; Girard R; Torbey M; Huang J; Huston J; Shu Y; Lanzino G; Selwyn R; Hart B; Mabray M; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar-Felix RJ; Shenkar R; Lane K; McBee N; Treine K; Ostapkovich N; Wang Y; Thompson R; Koenig JI; Carroll T; Hanley D; Awad I
Stroke; 2024 Jan; 55(1):22-30. PubMed ID: 38134268
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.
Polster SP; Stadnik A; Akers AL; Cao Y; Christoforidis GA; Fam MD; Flemming KD; Girard R; Hobson N; Koenig JI; Koskimäki J; Lane K; Liao JK; Lee C; Lyne SB; McBee N; Morrison L; Piedad K; Shenkar R; Sorrentino M; Thompson RE; Whitehead KJ; Zeineddine HA; Hanley DF; Awad IA
Neurosurgery; 2019 Dec; 85(6):843-853. PubMed ID: 30476251
[TBL] [Abstract][Full Text] [Related]
7. Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project.
Kim H; Flemming KD; Nelson JA; Lui A; Majersik JJ; Cruz MD; Zabramski J; Trevizo O; Lanzino G; Zafar A; Torbey M; Mabray MC; Robinson M; Narvid J; Lupo J; Thompson RE; Hanley DF; McBee N; Treine K; Ostapkovich N; Stadnik A; Piedad K; Hobson N; Carroll T; Shkoukani A; Carrión-Penagos J; Mendoza-Puccini C; Koenig JI; Awad I
Stroke; 2021 Dec; 52(12):3829-3838. PubMed ID: 34525838
[TBL] [Abstract][Full Text] [Related]
8. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).
Girard R; Li Y; Stadnik A; Shenkar R; Hobson N; Romanos S; Srinath A; Moore T; Lightle R; Shkoukani A; Akers A; Carroll T; Christoforidis GA; Koenig JI; Lee C; Piedad K; Greenberg SM; Kim H; Flemming KD; Ji Y; Awad IA
Neurosurgery; 2021 Feb; 88(3):686-697. PubMed ID: 33469662
[TBL] [Abstract][Full Text] [Related]
9. Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth.
Sone JY; Hobson N; Srinath A; Romanos SG; Li Y; Carrión-Penagos J; Shkoukani A; Stadnik A; Piedad K; Lightle R; Moore T; DeBiasse D; Bi D; Shenkar R; Carroll T; Ji Y; Girard R; Awad IA
J Magn Reson Imaging; 2022 May; 55(5):1440-1449. PubMed ID: 34558140
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping.
Tan H; Liu T; Wu Y; Thacker J; Shenkar R; Mikati AG; Shi C; Dykstra C; Wang Y; Prasad PV; Edelman RR; Awad IA
Invest Radiol; 2014 Jul; 49(7):498-504. PubMed ID: 24619210
[TBL] [Abstract][Full Text] [Related]
11. Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites.
Hobson N; Polster SP; Cao Y; Flemming K; Shu Y; Huston J; Gerrard CY; Selwyn R; Mabray M; Zafar A; Girard R; Carrión-Penagos J; Chen YF; Parrish T; Zhou XJ; Koenig JI; Shenkar R; Stadnik A; Koskimäki J; Dimov A; Turley D; Carroll T; Awad IA
J Magn Reson Imaging; 2020 Apr; 51(4):1192-1199. PubMed ID: 31515878
[TBL] [Abstract][Full Text] [Related]
12. Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).
Polster SP; Cao Y; Carroll T; Flemming K; Girard R; Hanley D; Hobson N; Kim H; Koenig J; Koskimäki J; Lane K; Majersik JJ; McBee N; Morrison L; Shenkar R; Stadnik A; Thompson RE; Zabramski J; Zeineddine HA; Awad IA
Neurosurgery; 2019 Apr; 84(4):954-964. PubMed ID: 29660039
[TBL] [Abstract][Full Text] [Related]
13. Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance.
Carrión-Penagos J; Zeineddine HA; Polster SP; Girard R; Lyne SB; Koskimäki J; Romanos S; Srinath A; Zhang D; Cao Y; Stadnik A; Piedad K; Shenkar R; Awad IA
J Neurosurg; 2020 Apr; 134(3):1147-1154. PubMed ID: 32244216
[TBL] [Abstract][Full Text] [Related]
14. Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage.
Sone JY; Li Y; Hobson N; Romanos SG; Srinath A; Lyne SB; Shkoukani A; Carrión-Penagos J; Stadnik A; Piedad K; Lightle R; Moore T; Li Y; Bi D; Shenkar R; Carroll T; Ji Y; Girard R; Awad IA
J Cereb Blood Flow Metab; 2021 Nov; 41(11):2944-2956. PubMed ID: 34039038
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations.
Tan H; Zhang L; Mikati AG; Girard R; Khanna O; Fam MD; Liu T; Wang Y; Edelman RR; Christoforidis G; Awad IA
AJNR Am J Neuroradiol; 2016 Jul; 37(7):1209-15. PubMed ID: 26965464
[TBL] [Abstract][Full Text] [Related]
16. Natural history of brainstem cavernous malformations: prospective hemorrhage rate and adverse factors in a consecutive prospective cohort.
Li D; Wu ZY; Liu PP; Ma JP; Huo XL; Wang L; Zhang LW; Wu Z; Zhang JT
J Neurosurg; 2020 Mar; 134(3):917-928. PubMed ID: 32168479
[TBL] [Abstract][Full Text] [Related]
17. The Influence of Physical Activity on Cavernous Malformation Hemorrhage.
Joseph NK; Kumar S; Lanzino G; Flemming KD
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104629. PubMed ID: 32147026
[TBL] [Abstract][Full Text] [Related]
18. Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations.
Mikati AG; Tan H; Shenkar R; Li L; Zhang L; Guo X; Larsson HB; Shi C; Liu T; Wang Y; Shah A; Edelman RR; Christoforidis G; Awad I
Stroke; 2014 Feb; 45(2):598-601. PubMed ID: 24302484
[TBL] [Abstract][Full Text] [Related]
19. Prospective Hemorrhage Rates of Cerebral Cavernous Malformations in Children and Adolescents Based on MRI Appearance.
Nikoubashman O; Di Rocco F; Davagnanam I; Mankad K; Zerah M; Wiesmann M
AJNR Am J Neuroradiol; 2015 Nov; 36(11):2177-83. PubMed ID: 26272978
[TBL] [Abstract][Full Text] [Related]
20. Zabramski classification in predicting the occurrence of symptomatic intracerebral hemorrhage in sporadic cerebral cavernous malformations.
Wang J; Yu QF; Huo R; Sun YF; Jiao YM; Xu HY; Zhang JZ; Zhao SZ; He QH; Wang S; Zhao JZ; Cao Y
J Neurosurg; 2024 Mar; 140(3):792-799. PubMed ID: 37724811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
